Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd
Cash from Operating Activities
Paradigm Biopharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Cash from Operating Activities
-AU$78.5m
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Cash from Operating Activities
-AU$35.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-10%
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$59.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$2.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Operating Activities
AU$42.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
AU$23.9m
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Paradigm Biopharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
-78.5m
AUD
Based on the financial report for Dec 31, 2023, Paradigm Biopharmaceuticals Ltd's Cash from Operating Activities amounts to -78.5m AUD.
What is Paradigm Biopharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-63%
Over the last year, the Cash from Operating Activities growth was -136%. The average annual Cash from Operating Activities growth rates for Paradigm Biopharmaceuticals Ltd have been -49% over the past three years , -63% over the past five years .